Financial Data and Key Metrics Changes - Invivyd's net revenues for Q4 2025 increased by 31% compared to Q3 2025 and by 25% compared to Q4 2024, totaling $53.4 million for the full year 2025 [26] - The company ended the year with $226.7 million in cash and cash equivalents, positioning it well for upcoming pivotal data for VYD2311 in mid-2026 [26] Business Line Data and Key Metrics Changes - The commercial work with PEMGARDA showed growth in Q4, establishing a foundation for broader commercialization of VYD2311 if approved [5] - The company reported a high reorder rate of 77% for PEMGARDA, indicating strong ongoing demand [24] Market Data and Key Metrics Changes - There is a growing recognition of monoclonal antibodies in the medical community, with leading organizations recommending their use for high-risk patients [22] - The company has secured over 15,000 contracted GPO sites, significantly expanding its commercial footprint [24] Company Strategy and Development Direction - Invivyd aims to redefine COVID prevention with its next-generation monoclonal antibody, moving towards a vaccine alternative strategy [25] - The company is focusing on expanding its portfolio to include treatments for other infectious diseases, such as RSV and measles, indicating a broader strategic vision [8][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for VYD2311 to provide effective protection against symptomatic COVID-19 [18] - The company is optimistic about the speed of study recruitment and the potential for robust assessment of VYD2311's effectiveness [20] Other Important Information - Invivyd is conducting its third randomized placebo-controlled trial for a COVID monoclonal antibody, which is designed to adapt to virus evolution [14] - The company is exploring the use of monoclonal antibodies for long COVID and post-vaccination syndrome, highlighting its commitment to addressing unmet medical needs [7] Q&A Session Summary Question: Can you elaborate on the potential trial resizing decision in the DECLARATION program? - Management indicated that the resizing decision would depend on the expected vaccine efficacy and the number of events accumulated, with a potential upsizing target of approximately 30% [29][30] Question: Are secondary endpoints being collected in the trial? - Management confirmed that various interactions, including healthcare utilization, would be recorded, but cautioned against expecting meaningful powering of low-frequency clinical events [34][35] Question: What is the envisioned use case for the measles antibody program? - Management highlighted potential use cases for outbreak prophylaxis and pediatric bridge therapy, emphasizing the antibody's design to address specific medical needs [37][41] Question: How is the DECLARATION study configured to target areas with high COVID rates? - Management explained that the study sites are strategically located in areas with community COVID attack rates, utilizing various data sources to inform site selection [46][48] Question: What is the approach to monitoring myocarditis in the study? - Management stated that the monitoring would primarily focus on clinical myocarditis events, with the possibility of further exploration if such events occur [50][51] Question: How does Invivyd plan to compete in the RSV antibody market? - Management expressed confidence in their antibody's properties and the potential to address evolutionary drift, positioning it as a competitive option in the RSV market [56][58]

Tonix Pharmaceuticals FY Conference Summary Company Overview - **Company Name**: Tonix Pharmaceuticals (NasdaqCM: TNXP) - **Focus**: Fully integrated pharmaceutical company with a focus on the launch of Tonmya, a treatment for fibromyalgia, and other therapeutic areas including migraine treatments [2][3] Key Products and Developments - **Tonmya**: - A sublingual cyclobenzaprine tablet approved for fibromyalgia treatment, launched on November 17, 2025 [4][6] - Targets disturbed sleep quality in fibromyalgia, addressing a high unmet need in a market with approximately 10 million adults affected in the U.S. [4][11] - Reported $1.4 million in net sales since launch [6] - Unique mechanism and first-in-class designation, with a focus on the 5% of prescribers who account for 70% of prescriptions [6][18] - **Migraine Treatments**: - Acquired two migraine products, Tosymra (sumatriptan nasal spray) and Zembrace (sumatriptan injection), but are gradually decreasing promotion of these products [19] Market Dynamics - **Fibromyalgia Market**: - High dissatisfaction with existing treatments, with only 3 million out of 10 million diagnosed and treated [12][13] - Potential for increased diagnosis among long COVID patients, with estimates suggesting 20-30 million may be affected [12] - Tonmya's pricing set at $1,860 per month for long-term use [18] - **Challenges and Opportunities**: - Need for education among prescribers about fibromyalgia and Tonmya [17][18] - Existing drugs for fibromyalgia are often misprescribed, with a significant reliance on opioids, which are not indicated for this condition [15][16] Clinical Pipeline - **Upcoming Studies**: - Lyme prophylactic program with promising phase one data, targeting a long-acting monoclonal antibody [27][28] - Studies for major depressive disorder and acute stress disorder funded by the U.S. Department of Defense [30] - Phase 2 study for kidney transplant treatment [31][32] Financial Position - **Financial Health**: - Ended the previous year with $208 million in cash and no debt, indicating a strong balance sheet [3] Conclusion - Tonix Pharmaceuticals is positioned for growth with a strong focus on addressing unmet needs in fibromyalgia and expanding its clinical pipeline. The company aims to leverage its unique product offerings and robust marketing strategies to capture a significant share of the market while navigating challenges in prescriber education and competition [33]

Core Viewpoint - Ratutrelvir demonstrates a differentiated clinical profile compared to PAXLOVID™, showing fewer adverse events and no viral rebounds, making it a promising treatment option for patients with mild-to-moderate COVID-19, including those ineligible for ritonavir-boosted therapies [1][5][12]. Group 1: Clinical Study Overview - Traws Pharma announced interim data from a Phase 2 clinical study of ratutrelvir, an oral, ritonavir-free protease inhibitor, which showed a favorable clinical profile in patients with mild-to-moderate COVID-19 [2][3]. - The study is an active-controlled trial comparing ratutrelvir to PAXLOVID™, with 37 patients included in the interim analysis, of which 25 received ratutrelvir and 12 received PAXLOVID™ [3][4]. - More than 50% of the planned 90-patient population has been enrolled in the study [3]. Group 2: Efficacy and Safety - Ratutrelvir-treated patients showed comparable time-to-sustained symptom alleviation to those treated with PAXLOVID™, with sustained alleviation defined as self-reported alleviation of all COVID-19 symptoms for four consecutive days [6]. - No COVID-19 symptom or virologic rebound events were observed in ratutrelvir-treated patients, while one rebound event occurred in the PAXLOVID™ group [7]. - Ratutrelvir was well tolerated, with fewer adverse events reported compared to the PAXLOVID™ cohort, where 30% of patients experienced adverse events [9][10]. Group 3: Implications for Long-COVID - The combination of early and sustained symptom improvement, absence of viral rebound, and favorable tolerability suggests that ratutrelvir may be useful in reducing post-acute sequelae of SARS-CoV-2 infection (Long COVID) [12]. - Ratutrelvir's design allows for broader patient use without the limitations associated with ritonavir, potentially offering a new approach to both acute COVID-19 treatment and prevention of long-term complications [12][13]. Group 4: Market Potential - The COVID treatment market represents a potential multi-billion dollar opportunity, with ratutrelvir positioned as a next-generation oral 3CL protease inhibitor that is ritonavir-free and has an improved tolerability profile [14].

Core Insights - Aethlon Medical, Inc. announced a pre-clinical study indicating the potential of the Hemopurifier device in treating Long COVID by targeting extracellular vesicles (EVs) [1][6][4] Company Overview - Aethlon Medical is focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device aimed at treating cancer and life-threatening viral infections [7][8] - The Hemopurifier has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses [8] Long COVID Context - Long COVID affects an estimated 44 to 48 million people in the U.S., with a projected economic burden of $2 billion for those experiencing symptoms for a year [2] - Symptoms include fatigue, shortness of breath, and cognitive difficulties, persisting for weeks or months after initial COVID-19 infection [2] Research Findings - The study published on November 20, 2025, demonstrated that the Hemopurifier can remove harmful EVs from the blood, which are implicated in Long COVID [1][5] - Elevated levels of both large and small EVs were found in the plasma of Long COVID patients compared to recovered controls, indicating a potential therapeutic target [5][6] - The GNA affinity resin in the Hemopurifier was shown to deplete specific microRNAs associated with inflammatory pathways, suggesting a mechanism for reducing inflammation in Long COVID [5][6] Future Directions - Aethlon Medical plans to further investigate whether the removal of EVs can decrease SARS-CoV-2 viral particles, which may contribute to Long COVID pathogenesis [6]

Core Insights - Traws Pharma is conducting a Phase 2 study to evaluate ratutrelvir, a ritonavir-free antiviral treatment for COVID-19, with top-line data expected by year-end 2025 [1][2][3] Group 1: Company Overview - Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for respiratory viral diseases [5] - The company aims to address critical health threats, including COVID-19, Long COVID, bird flu, and seasonal influenza [5] Group 2: Product Development - Ratutrelvir is designed as an oral, small molecule Mpro (3CL protease) inhibitor, showing in vitro activity against various virus strains [3] - The treatment does not require co-administration with ritonavir, potentially avoiding drug-drug interactions and expanding patient eligibility [3] - Phase 1 studies indicate that ratutrelvir maintains target blood plasma levels approximately 13 times above the EC50, which may reduce the likelihood of clinical rebound and Long COVID risk [3] Group 3: Clinical Trials - The first trial compares ratutrelvir against PAXLOVID, evaluating safety, infection rates, COVID symptoms, disease rebound, and Long COVID incidence [2] - A second trial will assess ratutrelvir's safety and efficacy in PAXLOVID-ineligible patients, a vulnerable population with limited treatment options [2] - Results from both Phase 2 studies are anticipated by the end of 2025 [2] Group 4: Market Potential - The COVID treatment market represents a potential multi-billion dollar opportunity, highlighting the significance of effective antiviral therapies [3]

Core Insights - Tevogen Bio Holdings Inc. emphasizes the potential of its investigational precision T cell therapy, TVGN 489, for treating Long COVID, which affects an estimated 20 million Americans [2][5] - Recent peer-reviewed studies indicate the presence of residual SARS-CoV-2 proteins and RNA long after acute infection, suggesting a viral reservoir that contributes to Long COVID symptoms [3] - TVGN 489 is designed to target multiple SARS-CoV-2 proteins across the entire viral genome, showing efficacy in reducing viral load and persisting in patients for at least 6 months without interfering with their immune responses [4] Scientific Evidence - Peer-reviewed studies published in notable journals report the detection of residual SARS-CoV-2 proteins and RNA for months to years post-infection, indicating chronic immune inflammation linked to Long COVID [3] - These findings support the development of therapeutic approaches aimed at eliminating residual virus and restoring immune homeostasis [3] Product Development - TVGN 489, derived from Tevogen's ExacTcell™ platform, is an off-the-shelf cytotoxic CD8+ T lymphocyte therapy targeting multiple viral proteins, not limited to the Spike protein [4] - In proof-of-concept trials, TVGN 489 demonstrated efficacy in reducing viral load across all patients, with CTLs persisting for at least 6 months [4] Company Outlook - The CEO of Tevogen expresses optimism regarding TVGN 489's potential to restore homeostasis in Long COVID patients, highlighting the company's preparations for clinical manufacturing [5]

Core Insights - Tevogen Bio Holdings Inc. expresses gratitude to the U.S. Department of Health and Human Services for addressing Long COVID through roundtables focused on patient experiences and research [1] - Approximately 20 million adults in the U.S. are affected by Long COVID, leading to significant economic consequences due to workforce absenteeism and productivity losses [2] - Tevogen's investigational drug, TVGN 489, shows promising results in clinical trials and may play a crucial role in addressing the Long COVID public health crisis [3] Company Developments - The CEO of Tevogen emphasizes the importance of addressing the lasting consequences of SARS-CoV-2, highlighting the potential of TVGN 489 to restore health for those affected by Long COVID [4] - Tevogen is committed to developing accessible and affordable personalized therapeutics through its ExacTcell™ platform, which focuses on precision T cell therapies [4]

Core Insights - Traws Pharma is advancing its antiviral programs targeting respiratory viruses, particularly focusing on ratutrelvir for COVID-19 and Tivoxavir marboxil (TXM) for influenza, in response to ongoing health threats and the need for effective treatments [1][20] - The company has submitted a Phase 2 study for ratutrelvir to evaluate its efficacy against PAXLOVID in newly diagnosed COVID patients, with results expected by the end of 2025 [3][5] - TXM is being positioned for stockpiling readiness, with ongoing discussions with BARDA for inclusion in pandemic preparedness initiatives [2][5] Product Development - Ratutrelvir is a ritonavir-free oral protease inhibitor designed for once-daily dosing over 10 days, showing promising Phase 1 results with plasma drug levels maintained significantly above the effective concentration [5][15] - TXM is an investigational single-dose treatment for bird flu and seasonal influenza, demonstrating strong preclinical efficacy against H5N1 and good tolerability in animal models [5][16] - The U.S. market opportunity for both products is estimated to be multi-billion dollars, driven by the ongoing need for effective antiviral treatments [5][15][16] Financial Performance - For Q2 2025, Traws reported revenue of $2.7 million, a significant increase from $57,000 in the same period in 2024, primarily due to deferred revenue recognition from a terminated licensing agreement [11][27] - Research and development expenses decreased to $2.3 million from $4.0 million year-over-year, reflecting a strategic shift in focus towards virology programs [12][13] - The net loss for Q2 2025 was $0.9 million, a substantial improvement compared to a net loss of $123.1 million in Q2 2024, which included a one-time charge related to an acquisition [13][29] Management and Corporate Updates - Traws will host a business update call on August 14, 2025, to discuss its Q2 results and pipeline progress [8] - Recent management changes include the appointment of Jack Stover as Chairman of the Board and Charles Parker as Interim CFO [13][21] - The company is actively seeking partnerships for its legacy oncology programs, including rigosertib and narazaciclib, to support further development [21]

Financial Data and Key Metrics Changes - As of June 30, 2025, the company had a cash balance of approximately $3.8 million [20] - For the three months ended June 30, 2025, consolidated operating expenses were approximately $1.8 million, down roughly $800,000 or 32% from $2.6 million a year ago [20][21] - The operating loss decreased to $1.8 million compared to $2.6 million from the previous year, reflecting progress in aligning resources with strategic priorities [21] Business Line Data and Key Metrics Changes - The company advanced its lead oncology indication clinical program and delivered preclinical results supporting broader applications, including long COVID, while significantly reducing operating expenses [7] - The first cohort of the Australian oncology trial completed Hemopurifier treatments without any device deficiencies or immediate complications [10] - An independent data safety monitoring board recommended advancing to the second treatment cohort after reviewing safety data from the first cohort [11] Market Data and Key Metrics Changes - The Australian oncology trial is designed to include patients on either monotherapy or combination therapy, increasing the potential pool of patients for the study [12] - The global economic burden of long COVID is approximately $1 trillion per year, indicating a large unmet medical need [15] Company Strategy and Development Direction - The company decided not to proceed with the India study to focus resources on the Australian trial, which is seen as the fastest track toward regulatory approval [7][8] - The focus remains on moving the Hemopurifier towards regulatory approval and expanding its use across multiple diseases [7] Management Comments on Operating Environment and Future Outlook - Management acknowledged the need to continue raising funds for clinical research, ideally through strategic partnerships rather than financial investors [31] - The decision to halt the Indian trial was primarily strategic, aimed at avoiding potential delays in moving forward to the PMA phase [31][34] Other Important Information - The company presented preclinical data on long COVID at a symposium, indicating the potential for the Hemopurifier to remove extracellular vesicles associated with long COVID [15][16] - The company is actively recruiting additional sites in Australia to speed up patient enrollment for the clinical trial [42] Q&A Session Summary Question: Is the primary endpoint of the Australian study safety, and is the company on track to meet it? - Management confirmed that the first cohort has been treated without adverse events, indicating progress towards meeting the primary endpoint [25][26] Question: How does the preclinical data translate to actual patient treatment? - Management acknowledged that lab results may not directly reflect patient outcomes, emphasizing the importance of data from actual patients [27][28] Question: What are the implications of not moving forward with the Indian trial? - Management stated that the decision was strategic to avoid delays in regulatory approval, although cost savings were also a factor [30][31][34] Question: Will the company be able to speed up enrollment in the Australian trial? - Management confirmed efforts to speed up enrollment, including recruiting additional sites and using clinical trial liaisons and social media campaigns [41][42]

Core Insights - Invivyd, Inc. has announced the addition of Dr. Akiko Iwasaki to the SPEAR Study Group, which focuses on the biology and clinical implications of persistent SARS-CoV-2 spike antigen [1][2] - The SPEAR Study Group aims to assess the safety and exploratory efficacy of monoclonal antibodies in individuals suffering from Long COVID and COVID-19 Post-Vaccination Syndrome (PVS) [3][4] Company Developments - Dr. Iwasaki is recognized for her research on viral pathogenesis and post-viral chronic conditions, including Long COVID, and leads several studies related to these areas [2] - The SPEAR Study Group was established in response to reports suggesting symptom improvement in Long COVID patients following administration of PEMGARDA, a monoclonal antibody authorized for emergency use [3][4] - Invivyd is utilizing monoclonal antibody technology to provide therapeutic options for individuals affected by Long COVID and PVS [3][4] Product Information - PEMGARDA (pemivibart) is an investigational monoclonal antibody with demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants [5][6] - VYD2311 is a novel monoclonal antibody candidate being developed to address the urgent need for new COVID-19 prophylactic and therapeutic options [11][12] - Both PEMGARDA and VYD2311 are engineered to target the SARS-CoV-2 spike protein, aiming to inhibit virus attachment to human cells [5][12]